NCT02500927View on ClinicalTrials.gov

A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

PHASE2TerminatedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

June 25, 2015

Primary Completion Date

June 9, 2017

Study Completion Date

June 9, 2017

Conditions
EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations
Interventions
DRUG

ASP8273 Capsules

oral

DRUG

ASP8273 Capsules A

oral

Trial Locations (11)

Unknown

Site: 5, Fukuoka

Site: 9, Hiroshima

Site: 8, Hyōgo

Site: 7, Kanagawa

Site: 11, Miyagi

Site: 1, Miyagi

Site: 10, Nagoya

Site: 4, Okayama

Site: 3, Osaka

Site: 6, Osaka

Site: 2, Tokyo

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY